Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine kinase activity of the EGFR. Here, we review the mechanism(s) of action of erlotinib, as well as the ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...

The specter of elevated liver enzymes, a known problem with the drug class, became a topic of talk with regard to Sanofi SA’s ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...